Semaglutide (Ozempic / Wegovy): An Evidence Review

Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn’t.

What it is

Semaglutide copies a hormone your gut releases after you eat, called GLP-1 (glucagon-like peptide-1). Technically it’s a “GLP-1 receptor agonist” — meaning it switches on the same receptors (docking sites on cells) that the natural hormone does. When it activates those receptors in the pancreas, gut, and brain, three things happen: your body releases more insulin when blood sugar is high, your stomach empties more slowly, and your appetite goes down.

You’ll see it under three brand names. Ozempic is a weekly shot for type 2 diabetes. Wegovy is a higher-dose weekly shot for weight management. Rybelsus is a daily pill for diabetes. In January 2026, the FDA also approved an oral tablet version of Wegovy for ongoing weight management — the first GLP-1 pill cleared for that purpose.

The claims

The mainstream claims are easy to state: real weight loss, better blood-sugar control in type 2 diabetes, and a lower risk of heart attack and stroke in certain patients. Off-label and online, people also push it for cosmetic weight loss in folks who aren’t obese, and increasingly for things like addiction — claims that are far shakier.

What the evidence actually shows

The core claims rest on large randomized controlled trials (studies where people are randomly assigned to the drug or a dummy treatment, the gold standard for sorting cause from coincidence) — not just personal stories.

• Weight: In the STEP 1 trial (Wilding et al., NEJM 2021; about 1,960 adults without diabetes), the weekly 2.4 mg dose led to roughly 14.9% mean weight loss over 68 weeks versus 2.4% on placebo (the dummy treatment), with diet and exercise alongside.
• Blood sugar: The SUSTAIN program showed meaningful drops in HbA1c (a blood test that reflects your average blood sugar over a few months) and in weight for people with type 2 diabetes, which is what backed the original Ozempic approval.
• Heart outcomes: The SELECT trial (17,604 adults who had existing cardiovascular disease and were overweight or obese, but did not have diabetes) found a 20% reduction in major adverse cardiovascular events — heart attack, stroke, and death from heart causes (hazard ratio 0.80, meaning the drug group’s risk was 80% of the placebo group’s) — over an average of about four years.

Two honest caveats. First, the benefits depend on staying on it — the weight tends to come back after you stop. Second, the heart benefit is clearest in people who already have heart disease plus excess weight. It doesn’t automatically carry over to healthy people taking the drug just for looks.

Legal and regulatory status

Semaglutide is an FDA-approved prescription drug — not a supplement, not a research chemical. Its approved uses cover type 2 diabetes (Ozempic, Rybelsus), ongoing weight management (Wegovy, now as both an injection and an oral tablet), and lowering heart risk in adults who have established heart disease plus overweight or obesity (Wegovy, approved March 2024). For athletes: semaglutide is not banned under the 2026 WADA Prohibited List (WADA is the World Anti-Doping Agency, which sets the rules for sport). But it has been on WADA’s Monitoring Program since 2024, which means its use is being tracked and the rules could change in a future update.

Safety

The most common side effects hit the gut — nausea, vomiting, diarrhea, constipation — and they’re usually worst while the dose is being raised. Less common but documented risks include gallbladder disease and gallstones and, more rarely, pancreatitis (inflammation of the pancreas). It also carries a boxed warning (the FDA’s strongest warning label) for thyroid C-cell tumors, based on studies in rodents, and it should not be used by anyone with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or MEN2 (an inherited condition that raises the risk of certain tumors). Whether it actually causes these tumors in people isn’t known, and no clear human cancer signal has been established. One more thing: big weight loss also strips away some lean muscle, which strength training and getting enough protein may partly make up for. None of this is medical advice — these drugs need a prescription and proper monitoring.

Bottom line

Semaglutide genuinely works for weight loss, blood-sugar control, and lowering heart risk in the groups that were studied, and its risks are real but usually manageable with medical supervision. The evidence is unusually solid. The open questions are mostly about the long haul: what happens with years of use, how well results last after stopping, and how it behaves in people outside the original trial groups.

Evidence grade: 10/10 · Established.

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021
• Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 2024 (PMC)
• Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology, 2021 (PMC)
• Semaglutide — StatPearls, NCBI Bookshelf
• FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (Wegovy, March 8, 2024)
• FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss (OASIS 4). AJMC, 2026
• WADA publishes 2026 Prohibited List